Comparison of the mechanisms of drug resistance among HIV, hepatitis B, and hepatitis C

Viruses

Volumn 2, Issue 12, 2010, Pages 2696-2739

  Margeridon Thermet, Severine ^a   Shafer, Robert W ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Antiviral therapy; Drug resistance; Evolution; HBV; HCV; HIV; Quasispecies

Indexed keywords

ADEFOVIR; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; INTEGRASE INHIBITOR; INTERFERON; LAMIVUDINE; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; SINGLE STRANDED RNA; STAVUDINE; TELBIVUDINE; TIPRANAVIR; UNINDEXED DRUG; VIRUS ENVELOPE PROTEIN; ZIDOVUDINE;

5' UNTRANSLATED REGION; ANTIVIRAL RESISTANCE; CD4+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DEAMINATION; EPIGENETICS; GENE MUTATION; GENE SILENCING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSTIMULATION; INNATE IMMUNITY; LENTIVIRINAE; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; REVIEW; VIRION; VIRUS REPLICATION; VIRUS TRANSMISSION;

DNA VIRUSES; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 79952151929     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2122696     Document Type: Review

References (311)

1. Han, Y.; Wind-Rotolo, M.; Yang, H.C.; Siliciano, J.D.; Siliciano, R.F. Experimental approaches to the study of HIV-1 latency. Nat. Rev. Microbiol. 2007, 5, 95-106.
2. Richman, D.D.; Margolis, D.M.; Delaney, M.; Greene, W.C.; Hazuda, D.; Pomerantz, R.J. The challenge of finding a cure for HIV infection. Science 2009, 323, 1304-1307.
3. Kay, A.; Zoulim, F. Hepatitis B virus genetic variability and evolution. Virus Res. 2007, 127, 164-176.
4. Werle-Lapostolle, B.; Bowden, S.; Locarnini, S.; Wursthorn, K.; Petersen, J.; Lau, G.; Trepo, C.; Marcellin, P.; Goodman, Z.; Delaney, W.E.T; et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004, 126, 1750-1758.
5. Levrero, M.; Pollicino, T.; Petersen, J.; Belloni, L.; Raimondo, G.; Dandri, M. Control of cccDNA function in hepatitis B virus infection. J. Hepatol. 2009, 51, 581-592.
6. Yang, P.L.; Althage, A.; Chung, J.; Maier, H.; Wieland, S.; Isogawa, M.; Chisari, F.V. Immune effectors required for hepatitis B virus clearance. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 798-802.
7. Guidotti, L.G.; Rochford, R.; Chung, J.; Shapiro, M.; Purcell, R.; Chisari, F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284, 825-829.
8. Ganem, D.; Prince, A.M. Hepatitis B virus infection--natural history and clinical consequences. N. Engl. J. Med. 2004, 350, 1118-1129.
9. Kenny-Walsh, E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N. Engl. J. Med. 1999, 340, 1228-1233.
10. Thomas, D.L.; Astemborski, J.; Rai, R.M.; Anania, F.A.; Schaeffer, M.; Galai, N.; Nolt, K.; Nelson, K.E.; Strathdee, S.A.; Johnson, L.; et al. The natural history of hepatitis C virus infection: Host, viral, and environmental factors. JAMA 2000, 284, 450-456.
11. Seeff, L.B.; Hollinger, F.B.; Alter, H.J.; Wright, E.C.; Cain, C.M.; Buskell, Z.J.; Ishak, K.G.; Iber, F.L.; Toro, D.; Samanta, A.; et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001, 33, 455-463.
12. Thompson, A.J.; Muir, A.J.; Sulkowski, M.S.; Ge, D.; Fellay, J.; Shianna, K.V.; Urban, T.; Afdhal, N.H.; Jacobson, I.M.; Esteban, R.; et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139, 120-129.e118.
13. Keele, B.F.; Jones, J.H.; Terio, K.A.; Estes, J.D.; Rudicell, R.S.; Wilson, M.L.; Li, Y.; Learn, G.H.; Beasley, T.M.; Schumacher-Stankey, J.; et al. Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature 2009, 460, 515-519.
14. Bar, K.J.; Li, H.; Chamberland, A.; Tremblay, C.; Routy, J.P.; Grayson, T.; Sun, C.; Wang, S.; Learn, G.H.; Morgan, C.J.; et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J. Virol. 2010, 84, 6241-6247.
15. Watts, J.M.; Dang, K.K.; Gorelick, R.J.; Leonard, C.W.; Bess, J.W., Jr.; Swanstrom, R.; Burch, C.L.; Weeks, K.M. Architecture and secondary structure of an entire HIV-1 RNA genome. Nature 2009, 460, 711-716.
16. Davis, M.; Sagan, S.M.; Pezacki, J.P.; Evans, D.J.; Simmonds, P. Bioinformatic and physical characterizations of genome-scale ordered RNA structure in mammalian RNA viruses. J. Virol. 2008, 82, 11824-11836.
17. Jenkins, G.M.; Worobey, M.; Woelk, C.H.; Holmes, E.C. Evidence for the non-quasispecies evolution of RNA viruses [corrected]. Mol. Biol. Evol. 2001, 18, 987-994.
18. Wilke, C.O. Quasispecies theory in the context of population genetics. BMC Evol. Biol. 2005, 5, 44.
19. Perelson, A.S.; Neumann, A.U.; Markowitz, M.; Leonard, J.M.; Ho, D.D. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271, 1582-1586.
20. Svarovskaia, E.S.; Cheslock, S.R.; Zhang, W.H.; Hu, W.S.; Pathak, V.K. Retroviral mutation rates and reverse transcriptase fidelity. Front. Biosci. 2003, 8, d117-d134.
21. Abram, M.E.; Ferris, A.L.; Shao, W.; Alvord, W.G.; Hughes, S.H. Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J. Virol. 2010, 84, 9864-9878.
22. Mansky, L.M. Forward mutation rate of human immunodeficiency virus type 1 in a T lymphoid cell line. AIDS Res. Hum. Retrovirus. 1996, 12, 307-314.
23. Coutsinos, D.; Invernizzi, C.F.; Xu, H.; Moisi, D.; Oliveira, M.; Brenner, B.G.; Wainberg, M.A. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J. Virol. 2009, 83, 2029-2033.
24. Hu, W.S.; Temin, H.M. Genetic consequences of packaging two RNA genomes in one retroviral particle: Pseudodiploidy and high rate of genetic recombination. Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 1556-1560.
25. Levy, D.N.; Aldrovandi, G.M.; Kutsch, O.; Shaw, G.M. Dynamics of HIV-1 recombination in its natural target cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 4204-4209.
26. Ramirez, B.C.; Simon-Loriere, E.; Galetto, R.; Negroni, M. Implications of recombination for HIV diversity. Virus Res. 2008, 134, 64-73.
27. Neher, R.A.; Leitner, T. Recombination rate and selection strength in HIV intra-patient evolution. PLoS Comput. Biol. 2010, 6, e1000660.
28. Galli, A.; Kearney, M.; Nikolaitchik, O.A.; Yu, S.; Chin, M.P.; Maldarelli, F.; Coffin, J.M.; Pathak, V.K.; Hu, W.S. Patterns of Human Immunodeficiency Virus type 1 recombination ex vivo provide evidence for coadaptation of distant sites, resulting in purifying selection for intersubtype recombinants during replication. J. Virol. 2010, 84, 7651-7661.
29. Shankarappa, R.; Margolick, J.B.; Gange, S.J.; Rodrigo, A.G.; Upchurch, D.; Farzadegan, H.; Gupta, P.; Rinaldo, C.R.; Learn, G.H.; He, X.; et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J. Virol. 1999, 73, 10489-10502.
30. Piantadosi, A.; Chohan, B.; Panteleeff, D.; Baeten, J.M.; Mandaliya, K.; Ndinya-Achola, J.O.; Overbaugh, J. HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response. AIDS 2009, 23, 579-587.
31. Kearney, M.; Maldarelli, F.; Shao, W.; Margolick, J.B.; Daar, E.S.; Mellors, J.W.; Rao, V.; Coffin, J.M.; Palmer, S. Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J. Virol. 2009, 83, 2715-2727.
32. Cullen, B.R. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J. Virol. 2006, 80, 1067-1076.
33. Kieffer, T.L.; Kwon, P.; Nettles, R.E.; Han, Y.; Ray, S.C.; Siliciano, R.F. G→A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J. Virol. 2005, 79, 1975-1980.
34. Gifford, R.J.; Rhee, S.Y.; Eriksson, N.; Liu, T.F.; Kiuchi, M.; Das, A.K.; Shafer, R.W. Sequence editing by Apolipoprotein B RNA-editing catalytic component [corrected] and epidemiological surveillance of transmitted HIV-1 drug resistance. AIDS 2008, 22, 717-725.
35. Jern, P.; Russell, R.A.; Pathak, V.K.; Coffin, J.M. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog. 2009, 5, e1000367.
36. Nowak, M.A.; Bonhoeffer, S.; Hill, A.M.; Boehme, R.; Thomas, H.C.; McDade, H. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 4398-4402.
37. Whalley, S.A.; Murray, J.M.; Brown, D.; Webster, G.J.; Emery, V.C.; Dusheiko, G.M.; Perelson, A.S. Kinetics of acute hepatitis B virus infection in humans. J. Exp. Med. 2001, 193, 847-854.
38. Ho, S.K.; Yam, W.C.; Leung, E.T.; Wong, L.P.; Leung, J.K.; Lai, K.N.; Chan, T.M. Rapid quantification of hepatitis B virus DNA by real-time PCR using fluorescent hybridization probes. J. Med. Microbiol. 2003, 52, 397-402.
39. Murray, J.M.; Purcell, R.H.; Wieland, S.F. The half-life of hepatitis B virions. Hepatology 2006, 44, 1117-1121.
40. Dandri, M.; Murray, J.M.; Lutgehetmann, M.; Volz, T.; Lohse, A.W.; Petersen, J. Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia. Hepatology 2008, 48, 1079-1086.
41. Herz, A.V.; Bonhoeffer, S.; Anderson, R.M.; May, R.M.; Nowak, M.A. Viral dynamics in vivo: Limitations on estimates of intracellular delay and virus decay. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 7247-7251.
42. Hannoun, C.; Horal, P.; Lindh, M. Long-term mutation rates in the hepatitis B virus genome. J. Gen. Virol. 2000, 81, 75-83.
43. Fares, M.A.; Holmes, E.C. A revised evolutionary history of hepatitis B virus (HBV). J. Mol. Evol. 2002, 54, 807-814.
44. Osiowy, C.; Giles, E.; Tanaka, Y.; Mizokami, M.; Minuk, G.Y. Molecular evolution of hepatitis B virus over 25 years. J. Virol. 2006, 80, 10307-10314.
45. Drake, J.W.; Charlesworth, B.; Charlesworth, D.; Crow, J.F. Rates of spontaneous mutation. Genetics 1998, 148, 1667-1686.
46. Khudyakov, Y. Coevolution and HBV drug resistance. Antivir. Ther. 2010, 15, 505-515.
47. Simmonds, P.; Midgley, S. Recombination in the genesis and evolution of hepatitis B virus genotypes. J. Virol. 2005, 79, 15467-15476.
48. Gunther, S. Genetic variation in HBV infection: Genotypes and mutants. J. Clin. Virol. 2006, 36, S3-S11.
49. Guidotti, L.G.; Chisari, F.V. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 2006, 1, 23-61.
50. Mizokami, M.; Orito, E.; Ohba, K.; Ikeo, K.; Lau, J.Y.; Gojobori, T. Constrained evolution with respect to gene overlap of hepatitis B virus. J. Mol. Evol. 1997, 44, S83-S90.
51. Zaaijer, H.L.; van Hemert, F.J.; Koppelman, M.H.; Lukashov, V.V. Independent evolution of overlapping polymerase and surface protein genes of hepatitis B virus. J. Gen. Virol. 2007, 88, 2137-2143.
52. Soriano, V.; Perelson, A.S.; Zoulim, F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J. Antimicrob. Chemother. 2008, 62, 1-4.
53. Lim, S.G.; Cheng, Y.; Guindon, S.; Seet, B.L.; Lee, L.Y.; Hu, P.; Wasser, S.; Peter, F.J.; Tan, T.; Goode, M.; et al. Viral quasi-species evolution during hepatitis Be antigen seroconversion. Gastroenterology 2007, 133, 951-958.
54. Chen, L.; Zhang, Q.; Yu, D.M.; Wan, M.B.; Zhang, X.X. Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy. J. Hepatol. 2009, 50, 895-905.
55. Margeridon-Thermet, S.; Shulman, N.S.; Ahmed, A.; Shahriar, R.; Liu, T.; Wang, C.; Holmes, S.P.; Babrzadeh, F.; Gharizadeh, B.; Hanczaruk, B.; et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J. Infect. Dis. 2009, 199, 1275-1285.
56. Pallier, C.; Rodriguez, C.; Brillet, R.; Nordmann, P.; Hezode, C.; Pawlotsky, J.M. Complex dynamics of hepatitis B Virus Res.istance to adefovir. Hepatology 2009, 49, 50-59.
57. Pallier, C.; Castera, L.; Soulier, A.; Hezode, C.; Nordmann, P.; Dhumeaux, D.; Pawlotsky, J.M. Dynamics of hepatitis B Virus Res.istance to lamivudine. J. Virol. 2006, 80, 643-653.
58. Suspene, R.; Guetard, D.; Henry, M.; Sommer, P.; Wain-Hobson, S.; Vartanian, J.P. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 8321-8326.
59. Noguchi, C.; Ishino, H.; Tsuge, M.; Fujimoto, Y.; Imamura, M.; Takahashi, S.; Chayama, K. G to A hypermutation of hepatitis B virus. Hepatology 2005, 41, 626-633.
60. Reuman, E.C.; Margeridon-Thermet, S.; Caudill, H.B.; Liu, T.; Borroto-Esoda, K.; Svarovskaia, E.S.; Holmes, S.; Shafer, R.W. A classification model for G-to-A hypermutation in hepatitis B virus ultra-deep pyrosequencing reads. Bioinformatics 2010, 26, 2929-2932.
61. Pawlotsky, J.M. Use and interpretation of virological tests for hepatitis C. Hepatology 2002, 36, S65-S73.
62. Neumann, A.U.; Lam, N.P.; Dahari, H.; Gretch, D.R.; Wiley, T.E.; Layden, T.J.; Perelson, A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282, 103-107.
63. Ramratnam, B.; Bonhoeffer, S.; Binley, J.; Hurley, A.; Zhang, L.; Mittler, J.E.; Markowitz, M.; Moore, J.P.; Perelson, A.S.; Ho, D.D. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999, 354, 1782-1785.
64. Herrmann, E.; Neumann, A.U.; Schmidt, J.M.; Zeuzem, S. Hepatitis C virus kinetics. Antivir. Ther. 2000, 5, 85-90.
65. Guo, J.T.; Bichko, V.V.; Seeger, C. Effect of alpha interferon on the hepatitis C virus replicon. J. Virol. 2001, 75, 8516-8523.
66. Ogata, N.; Alter, H.J.; Miller, R.H.; Purcell, R.H. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 3392-3396.
67. Smith, D.B.; Pathirana, S.; Davidson, F.; Lawlor, E.; Power, J.; Yap, P.L.; Simmonds, P. The origin of hepatitis C virus genotypes. J. Gen. Virol. 1997, 78 (Pt 2), 321-328.
68. Powdrill, M.; Bernatchez, J.; Gotte, M. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase NS5B. Viruses 2010, 2, 2169-2195.
69. Simmonds, P. Genetic diversity and evolution of hepatitis C virus--15 years on. J. Gen. Virol. 2004, 85, 3173-3188.
70. Kalinina, O.; Norder, H.; Mukomolov, S.; Magnius, L.O. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J. Virol. 2002, 76, 4034-4043.
71. Colina, R.; Casane, D.; Vasquez, S.; Garcia-Aguirre, L.; Chunga, A.; Romero, H.; Khan, B.; Cristina, J. Evidence of intratypic recombination in natural populations of hepatitis C virus. J. Gen. Virol. 2004, 85, 31-37.
72. Moreau, I.; Hegarty, S.; Levis, J.; Sheehy, P.; Crosbie, O.; Kenny-Walsh, E.; Fanning, L.J. Serendipitous identification of natural intergenotypic recombinants of hepatitis C in Ireland. Virol. J. 2006, 3, 95.
73. Mondelli, M.U.; Cerino, A.; Meola, A.; Nicosia, A. Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses. J. Biosci. 2003, 28, 305-310.
74. Sheridan, I.; Pybus, O.G.; Holmes, E.C.; Klenerman, P. High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J. Virol. 2004, 78, 3447-3454.
75. Erickson, A.L.; Kimura, Y.; Igarashi, S.; Eichelberger, J.; Houghton, M.; Sidney, J.; McKinney, D.; Sette, A.; Hughes, A.L.; Walker, C.M. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001, 15, 883-895.
76. Soderholm, J.; Ahlen, G.; Kaul, A.; Frelin, L.; Alheim, M.; Barnfield, C.; Liljestrom, P.; Weiland, O.; Milich, D.R.; Bartenschlager, R.; et al. Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut 2006, 55, 266-274.
77. Gale, M., Jr.; Foy, E.M. Evasion of intracellular host defence by hepatitis C virus. Nature 2005, 436, 939-945.
78. Martell, M.; Esteban, J.I.; Quer, J.; Genesca, J.; Weiner, A.; Esteban, R.; Guardia, J.; Gomez, J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution. J. Virol. 1992, 66, 3225-3229.
79. Manzin, A.; Solforosi, L.; Petrelli, E.; Macarri, G.; Tosone, G.; Piazza, M.; Clementi, M. Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J. Virol. 1998, 72, 6271-6276.
80. Cristina, J.; del Pilar Moreno, M.; Moratorio, G. Hepatitis C virus genetic variability in patients undergoing antiviral therapy. Virus Res. 2007, 127, 185-194.
81. Fan, X.; Mao, Q.; Zhou, D.; Lu, Y.; Xing, J.; Xu, Y.; Ray, S.C.; Di Bisceglie, A.M. High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy. Hepatology 2009, 50, 1765-1772.
82. Hemelaar, J.; Gouws, E.; Ghys, P.D.; Osmanov, S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006, 20, W13-W23.
83. McCutchan, F.E. Global epidemiology of HIV. J. Med. Virol. 2006, 78, S7-S12.
84. Parkin, N.T.; Schapiro, J.M. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir. Ther. 2004, 9, 3-12.
85. Kantor, R.; Katzenstein, D.A.; Efron, B.; Carvalho, A.P.; Wynhoven, B.; Cane, P.; Clarke, J.; Sirivichayakul, S.; Soares, M.A.; Snoeck, J.; et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med. 2005, 2, e112.
86. Cane, P.A.; de Ruiter, A.; Rice, P.; Wiselka, M.; Fox, R.; Pillay, D. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom. J. Clin. Microbiol. 2001, 39, 2652-2654.
87. Sugiura, W.; Matsuda, Z.; Yokomaku, Y.; Hertogs, K.; Larder, B.; Oishi, T.; Okano, A.; Shiino, T.; Tatsumi, M.; Matsuda, M.; et al. Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2002, 46, 708-715.
88. Brenner, B.; Turner, D.; Oliveira, M.; Moisi, D.; Detorio, M.; Carobene, M.; Marlink, R.G.; Schapiro, J.; Roger, M.; Wainberg, M.A. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003, 17, F1-F5.
89. Grossman, Z.; Istomin, V.; Averbuch, D.; Lorber, M.; Risenberg, K.; Levi, I.; Chowers, M.; Burke, M.; Bar Yaacov, N.; Schapiro, J.M. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 2004, 18, 909-915.
90. Grossman, Z.; Paxinos, E.E.; Averbuch, D.; Maayan, S.; Parkin, N.T.; Engelhard, D.; Lorber, M.; Istomin, V.; Shaked, Y.; Mendelson, E.; et al. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob. Agents Chemother. 2004, 48, 2159-2165.
91. Camacho, R.; Godinho, A.; Gomes, P.; Abecasis, A.; Vandamme, A.-M.; Palma, C.; Carvalho, A.P.; Cabanas, J.; Goncalves, J. Different substitutions under drug pressure at protease codon 82 in HIV-1 subtype G compared to subtype B infected individuals including a novel I82M resistance mutations [abstract 138]. Antivir. Ther. 2005, 10, S151.
92. Martinez-Cajas, J.L.; Pai, N.P.; Klein, M.B.; Wainberg, M.A. Differences in resistance mutations among HIV-1 non-subtype B infections: A systematic review of evidence (1996-2008). J. Int. AIDS Soc. 2009, 12, 11.
93. Doualla-Bell, F.; Avalos, A.; Brenner, B.; Gaolathe, T.; Mine, M.; Gaseitsiwe, S.; Oliveira, M.; Moisi, D.; Ndwapi, N.; Moffat, H.; et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob. Agents Chemother. 2006, 50, 4182-4185.
94. Hosseinipour, M.C.; van Oosterhout, J.J.; Weigel, R.; Phiri, S.; Kamwendo, D.; Parkin, N.; Fiscus, S.A.; Nelson, J.A.; Eron, J.J.; Kumwenda, J. The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009, 23, 1127-1134.
95. Invernizzi, C.F.; Coutsinos, D.; Oliveira, M.; Moisi, D.; Brenner, B.G.; Wainberg, M.A. Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J. Infect. Dis. 2009, 200, 1202-1206.
96. Stuyver, L.; De Gendt, S.; Van Geyt, C.; Zoulim, F.; Fried, M.; Schinazi, R.F.; Rossau, R. A new genotype of hepatitis B virus: Complete genome and phylogenetic relatedness. J. Gen. Virol. 2000, 81, 67-74.
97. Fung, S.K.; Lok, A.S. Hepatitis B virus genotypes: Do they play a role in the outcome of HBV infection? Hepatology 2004, 40, 790-792.
98. Liu, C.J.; Kao, J.H. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir. Ther. 2008, 13, 613-624.
99. Moucari, R.; Martinot-Peignoux, M.; Mackiewicz, V.; Boyer, N.; Ripault, M.P.; Castelnau, C.; Leclere, L.; Dauvergne, A.; Valla, D.; Vidaud, M.; et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir. Ther. 2009, 14, 1183-1188.
100. McMahon, B.J. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol. Int. 2009, 3, 334-342.
101. Liaw, Y.; Brunetto, M.; Hadziyannis, S. The natural history of chronic HBV infection and geographical differences. Antivir. Ther. 2010, 15, 25-33.
102. Zein, N.N. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. 2000, 13, 223-235.
103. Simmonds, P.; Bukh, J.; Combet, C.; Deleage, G.; Enomoto, N.; Feinstone, S.; Halfon, P.; Inchauspe, G.; Kuiken, C.; Maertens, G.; et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42, 962-973.
104. Simmonds, P. The origin and evolution of hepatitis viruses in humans. J. Gen. Virol. 2001, 82, 693-712.
105. Legrand-Abravanel, F.; Colson, P.; Leguillou-Guillemette, H.; Alric, L.; Ravaux, I.; Lunel-Fabiani, F.; Bouviers-Alias, M.; Trimoulet, P.; Chaix, M.L.; Hezode, C.; et al. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J. Med. Virol. 2009, 81, 2029-2035.
106. Ghany, M.G.; Strader, D.B.; Thomas, D.L.; Seeff, L.B. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009, 49, 1335-1374.
107. Phillips, A.N.; Miller, V.; Sabin, C.; Cozzi Lepri, A.; Klauke, S.; Bickel, M.; Doerr, H.W.; Hill, A.; Staszewski, S. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS 2001, 15, 2379-2384.
108. Bennett, D.; McCormick, L.; Kline, R.; Wheeler, W.; Hemmen, M.; Smith, A.; Zaidi, I.; Dondero, T. U.S. surveillance of HIV drug resistance at diagnosis using HIV diagnostic sera [Abstract 674]. In Proceeding of the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 22-25 February 2005.
109. Vercauteren, J.; Wensing, A.M.; van de Vijver, D.A.; Albert, J.; Balotta, C.; Hamouda, O.; Kucherer, C.; Struck, D.; Schmit, J.C.; Asjo, B.; et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J. Infect. Dis. 2009, 200, 1503-1508.
110. Geretti, A.M. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr. Opin. Infect. Dis. 2007, 20, 22-32.
111. Chan, P.; Kantor, R. Transmitted drug resistance in nonsubtype B HIV-1 infection. HIV Therapy 2009, 3, 447-465.
112. Meyer, P.R.; Matsuura, S.E.; Schinazi, R.F.; So, A.G.; Scott, W.A. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates. Antimicrob. Agents Chemother. 2000, 44, 3465-3472.
113. Lennerstrand, J.; Stammers, D.K.; Larder, B.A. Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. Antimicrob. Agents Chemother. 2001, 45, 2144-2146.
114. Whitcomb, J.M.; Parkin, N.T.; Chappey, C.; Hellmann, N.S.; Petropoulos, C.J. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J. Infect. Dis. 2003, 188, 992-1000.
115. Sarafianos, S.G.; Das, K.; Hughes, S.H.; Arnold, E. Taking aim at a moving target: Designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr. Opin. Struct. Biol. 2004, 14, 716-730.
116. Arion, D.; Sluis-Cremer, N.; Parniak, M.A. Mechanism by which phosphonoformic acid resistance mutations restore 3'- azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase. J. Biol. Chem. 2000, 275, 9251-9255.
117. Lanier, E.R.; Ait-Khaled, M.; Scott, J.; Stone, C.; Melby, T.; Sturge, G.; St Clair, M.; Steel, H.; Hetherington, S.; Pearce, G.; et al. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir. Ther. 2004, 9, 37-45.
118. Molina, J.M.; Marcelin, A.G.; Pavie, J.; Heripret, L.; De Boever, C.M.; Troccaz, M.; Leleu, G.; Calvez, V. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: A randomized placebo-controlled trial. J. Infect. Dis. 2005, 191, 840-847.
119. Miller, M.D.; Margot, N.; Lu, B.; Zhong, L.; Chen, S.S.; Cheng, A.; Wulfsohn, M. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J. Infect. Dis. 2004, 189, 837-846.
120. Parikh, U.M.; Koontz, D.L.; Chu, C.K.; Schinazi, R.F.; Mellors, J.W. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob. Agents Chemother. 2005, 49, 1139-1144.
121. Gallant, J.E.; DeJesus, E.; Arribas, J.R.; Pozniak, A.L.; Gazzard, B.; Campo, R.E.; Lu, B.; McColl, D.; Chuck, S.; Enejosa, J.; et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 2006, 354, 251-260.
122. Winters, M.A.; Coolley, K.L.; Girard, Y.A.; Levee, D.J.; Hamdan, H.; Shafer, R.W.; Katzenstein, D.A.; Merigan, T.C. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J. Clin. Invest. 1998, 102, 1769-1775.
123. Masquelier, B.; Race, E.; Tamalet, C.; Descamps, D.; Izopet, J.; Buffet-Janvresse, C.; Ruffault, A.; Mohammed, A.S.; Cottalorda, J.; Schmuck, A.; et al. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): Multicenter study of patients treated with RT inhibitors. Antimicrob. Agents Chemother. 2001, 45, 1836-1842.
124. Shafer, R.W.; Kozal, M.J.; Winters, M.A.; Iversen, A.K.; Katzenstein, D.A.; Ragni, M.V.; Meyer, W.A.; Gupta, P.; Rasheed, S.; Coombs, R.; et al. Combination therapy with zidovudine and didanosine selects for drug- resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 1994, 169, 722-729.
125. Shirasaka, T.; Kavlick, M.F.; Ueno, T.; Gao, W.Y.; Kojima, E.; Alcaide, M.L.; Chokekijchai, S.; Roy, B.M.; Arnold, E.; Yarchoan, R.; et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 2398-2402.
126. Ehteshami, M.; Gotte, M. Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility. AIDS Rev. 2008, 10, 224-235.
127. Shahriar, R.; Rhee, S.Y.; Liu, T.F.; Fessel, W.J.; Scarsella, A.; Towner, W.; Holmes, S.P.; Zolopa, A.R.; Shafer, R.W. Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations. Antimicrob. Agents Chemother. 2009, 53, 4869-4878.
128. Gupta, S.; Fransen, S.; Paxinos, E.E.; Stawiski, E.; Huang, W.; Petropoulos, C.J. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: Assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance. Antimicrob. Agents Chemother. 2010, 54, 1973-1980.
129. Acosta-Hoyos, A.J.; Scott, W.A. The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance. Viruses 2010, 2, 372-394.
130. Nikolenko, G.N.; Delviks-Frankenberry, K.A.; Palmer, S.; Maldarelli, F.; Fivash, M.J., Jr.; Coffin, J.M.; Pathak, V.K. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 317-322.
131. Delviks-Frankenberry, K.A.; Nikolenko, G.N.; Pathak, V.K. The "connection" between HIV drug resistance and RNase H. Viruses 2010, 2, 1476-1503.
132. Parkin, N.T.; Hellmann, N.S.; Whitcomb, J.M.; Kiss, L.; Chappey, C.; Petropoulos, C.J. Natural variation of drug susceptibility in wild-type HIV-1. Antimicrob. Agents Chemother. 2004, 48, 437-443.
133. Jackson, J.B.; Becker-Pergola, G.; Guay, L.A.; Musoke, P.; Mracna, M.; Fowler, M.G.; Mofenson, L.M.; Mirochnick, M.; Mmiro, F.; Eshleman, S.H. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000, 14, F111-F115.
134. Jourdain, G.; Ngo-Giang-Huong, N.; Le Coeur, S.; Bowonwatanuwong, C.; Kantipong, P.; Leechanachai, P.; Ariyadej, S.; Leenasirimakul, P.; Hammer, S.; Lallemant, M. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med. 2004, 351, 229-240.
135. Vingerhoets, J.; Azijn, H.; Fransen, E.; De Baere, I.; Smeulders, L.; Jochmans, D.; Andries, K.; Pauwels, R.; de Bethune, M.P. TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J. Virol. 2005, 79, 12773-12782.
136. Vingerhoets, J.; Tambuyzer, L.; Azijn, H.; Hoogstoel, A.; Nijs, S.; Peeters, M.; de Bethune, M.P.; De Smedt, G.; Woodfall, B.; Picchio, G. Resistance profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010, 24, 503-514.
137. Das, K.; Clark, A.D., Jr.; Lewi, P.J.; Heeres, J.; De Jonge, M.R.; Koymans, L.M.; Vinkers, H.M.; Daeyaert, F.; Ludovici, D.W.; Kukla, M.J.; et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 2004, 47, 2550-2560.
138. Larder, B.A. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J. Gen. Virol. 1994, 75, 951-957.
139. Shulman, N.; Zolopa, A.R.; Passaro, D.; Shafer, R.W.; Huang, W.; Katzenstein, D.; Israelski, D.M.; Hellmann, N.; Petropoulos, C.; Whitcomb, J. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: Impact on virological response to efavirenz-based therapy. AIDS 2001, 15, 1125-1132.
140. Whitcomb, J.M.; Huang, W.; Limoli, K.; Paxinos, E.; Wrin, T.; Skowron, G.; Deeks, S.G.; Bates, M.; Hellmann, N.S.; Petropoulos, C.J. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: Clinical, phenotypic and genotypic correlates. AIDS 2002, 16, F41-F47.
141. Vermeiren, H.; Van Craenenbroeck, E.; Alen, P.; Bacheler, L.; Picchio, G.; Lecocq, P. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J. Virol. Methods 2007, 145, 47-55.
142. Rhee, S.Y.; Taylor, J.; Fessel, W.J.; Kaufman, D.; Towner, W.; Troia, P.; Ruane, P.; Hellinger, J.; Shirvani, V.; Zolopa, A.; et al. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob. Agents Chemother. 2010, 54, 4253-4261.
143. Erickson, J.W.; Gulnik, S.V.; Markowitz, M. Protease inhibitors: Resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 1999, 13, S189-S204.
144. Foulkes-Murzycki, J.E.; Scott, W.R.; Schiffer, C.A. Hydrophobic sliding: A possible mechanism for drug resistance in human immunodeficiency virus type 1 protease. Structure 2007, 15, 225-233.
145. Cote, H.C.; Brumme, Z.L.; Harrigan, P.R. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 2001, 75, 589-594.
146. Maguire, M.F.; Guinea, R.; Griffin, P.; Macmanus, S.; Elston, R.C.; Wolfram, J.; Richards, N.; Hanlon, M.H.; Porter, D.J.; Wrin, T.; et al. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J. Virol. 2002, 76, 7398-7406.
147. Kolli, M.; Lastere, S.; Schiffer, C.A. Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate. Virology 2006, 347, 405-409.
148. Nijhuis, M.; van Maarseveen, N.M.; Lastere, S.; Schipper, P.; Coakley, E.; Glass, B.; Rovenska, M.; de Jong, D.; Chappey, C.; Goedegebuure, I.W.; et al. A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism. PLoS Med. 2007, 4, e36.
149. Kempf, D.J.; Isaacson, J.D.; King, M.S.; Brun, S.C.; Xu, Y.; Real, K.; Bernstein, B.M.; Japour, A.J.; Sun, E.; Rode, R.A. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 2001, 75, 7462-7469.
150. De Meyer, S.; Azijn, H.; Surleraux, D.; Jochmans, D.; Tahri, A.; Pauwels, R.; Wigerinck, P.; de Bethune, M.P. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 2005, 49, 2314-2321.
151. Bierman, W.F.; van Agtmael, M.A.; Nijhuis, M.; Danner, S.A.; Boucher, C.A. HIV monotherapy with ritonavir-boosted protease inhibitors: A systematic review. AIDS 2009, 23, 279-291.
152. Arribas, J.R.; Horban, A.; Gerstoft, J.; Fatkenheuer, G.; Nelson, M.; Clumeck, N.; Pulido, F.; Hill, A.; van Delft, Y.; Stark, T.; et al. The MONET trial: Darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mL. AIDS 2010, 24, 223-230.
153. Katlama, C.; Valantin, M.A.; Algarte-Genin, M.; Duvivier, C.; Lambert-Niclot, S.; Girard, P.M.; Molina, J.M.; Hoen, B.; Pakianather, S.; Peytavin, G.; et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: A randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010, 24, 2365-2374.
154. Hazuda, D.J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J.A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; et al. Inhibitors of strand transfer that prevent integration and inhibit HIV- 1 replication in cells. Science 2000, 287, 646-650.
155. Johnson, A.A.; Santos, W.; Pais, G.C.; Marchand, C.; Amin, R.; Burke, T.R., Jr.; Verdine, G.; Pommier, Y. Integration requires a specific interaction of the donor DNA terminal 5'-cytosine with glutamine 148 of the HIV-1 integrase flexible loop. J. Biol. Chem. 2006, 281, 461-467.
156. McColl, D.J.; Chen, X. Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy. Antivir. Res. 2010, 85, 101-118.
157. Mouscadet, J.F.; Delelis, O.; Marcelin, A.G.; Tchertanov, L. Resistance to HIV-1 integrase inhibitors: A structural perspective. Drug Resist. Updat. 2010, 13, 139-150.
158. McColl, D.; Fransen, S.; Gupta, S.; Parking, N.; Margot, N.; Chuck, S.; Cheng, A.; Miller, M. Resistance and cross-resistance to first generation integrase inhibitors: Insights from a phase II study of elvitegravir (GS-9137) [abstract 9]. Antivir. Ther. 2007, 12, S11.
159. Shimura, K.; Kodama, E.; Sakagami, Y.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Watanabe, Y.; Ohata, Y.; Doi, S.; Sato, M.; et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 2008, 82, 764-774.
160. Kobayashi, M.; Nakahara, K.; Seki, T.; Miki, S.; Kawauchi, S.; Suyama, A.; Wakasa-Morimoto, C.; Kodama, M.; Endoh, T.; Oosugi, E.; et al. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antivir. Res. 2008, 80, 213-222.
161. Goethals, O.; Clayton, R.; Van Ginderen, M.; Vereycken, I.; Wagemans, E.; Geluykens, P.; Dockx, K.; Strijbos, R.; Smits, V.; Vos, A.; et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J. Virol. 2008, 82, 10366-10374.
162. Goethals, O.; Vos, A.; Van Ginderen, M.; Geluykens, P.; Smits, V.; Schols, D.; Hertogs, K.; Clayton, R. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. Virology 2010, 402, 338-346.
163. Fransen, S.; Gupta, S.; Danovich, R.; Hazuda, D.; Miller, M.; Witmer, M.; Petropoulos, C.J.; Huang, W. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J. Virol. 2009, 83, 11440-11446.
164. Delelis, O.; Malet, I.; Na, L.; Tchertanov, L.; Calvez, V.; Marcelin, A.G.; Subra, F.; Deprez, E.; Mouscadet, J.F. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucl. Acids Res. 2009, 37, 1193-1201.
165. Reuman, E.C.; Bachmann, M.H.; Varghese, V.; Fessel, W.J.; Shafer, R.W. Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector. Antimicrob. Agents Chemother. 2010, 54, 934-936.
166. Metifiot, M.; Maddali, K.; Naumova, A.; Zhang, X.; Marchand, C.; Pommier, Y. Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir. Biochemistry 2010, 49, 3715-3722.
167. Kilby, J.M.; Eron, J.J. Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med. 2003, 348, 2228-2238.
168. Sista, P.R.; Melby, T.; Davison, D.; Jin, L.; Mosier, S.; Mink, M.; Nelson, E.L.; DeMasi, R.; Cammack, N.; Salgo, M.P.; et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004, 18, 1787-1794.
169. Mink, M.; Mosier, S.M.; Janumpalli, S.; Davison, D.; Jin, L.; Melby, T.; Sista, P.; Erickson, J.; Lambert, D.; Stanfield-Oakley, S.A.; et al. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J. Virol. 2005, 79, 12447-12454.
170. Lu, J.; Deeks, S.G.; Hoh, R.; Beatty, G.; Kuritzkes, B.A.; Martin, J.N.; Kuritzkes, D.R. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: Results of a clonal analysis. J. Acquir. Immune Defic. Syndr. 2006, 43, 60-64.
171. Hartley, O.; Klasse, P.; Sattentau, Q.; Moore, J.P. V3: HIV's switch hitter. AIDS Res. Hum. Retrovirus. 2005, 21, 171-189.
172. Westby, M.; Smith-Burchnell, C.; Mori, J.; Lewis, M.; Mosley, M.; Stockdale, M.; Dorr, P.; Ciaramella, G.; Perros, M. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 2007, 81, 2359-2371.
173. Westby, M.; Lewis, M.; Whitcomb, J.; Youle, M.; Pozniak, A.L.; James, I.T.; Jenkins, T.M.; Perros, M.; van der Ryst, E. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using Virus Res.ervoir. J. Virol. 2006, 80, 4909-4920.
174. Moore, J.P.; Kuritzkes, D.R. A piece de resistance: How HIV-1 escapes small molecule CCR5 inhibitors. Curr. Opin. HIV AIDS 2009, 4, 118-124.
175. Soriano, V.; Perno, C.F.; Kaiser, R.; Calvez, V.; Gatell, J.M.; di Perri, G.; Pillay, D.; Rockstroh, J.; Geretti, A.M. When and how to use maraviroc in HIV-infected patients. AIDS 2009, 23, 2377-2385.
176. Tilton, J.C.; Doms, R.W. Entry inhibitors in the treatment of HIV-1 infection. Antivir. Res. 2010, 85, 91-100.
177. Shafer, R.W.; Schapiro, J.M. HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev. 2008, 10, 67-84.
178. Singh, K.; Marchand, B.; Kirby, K.A.; Michailidis, E.; Sarafianos, S.G. Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase. Viruses 2010, 2, 606-638.
179. Metifiot, M.; Marchand, C.; Maddali, K.; Pommier, Y. Resistance to integrase inhibitors. Viruses 2010, 2, 1347-1366.
180. Low, A.J.; Swenson, L.C.; Harrigan, P.R. HIV coreceptor phenotyping in the clinical setting. AIDS Rev. 2008, 10, 143-151.
181. Piccolo, P.; Lenci, I.; Demelia, L.; Bandiera, F.; Piras, M.R.; Antonucci, G.; Nosotti, L.; Mari, T.; De Santis, A.; Ponti, M.L.; et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir. Ther. 2009, 14, 1165-1174.
182. Moucari, R.; Korevaar, A.; Lada, O.; Martinot-Peignoux, M.; Boyer, N.; Mackiewicz, V.; Dauvergne, A.; Cardoso, A.C.; Asselah, T.; Nicolas-Chanoine, M.H.; et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study. J. Hepatol. 2009, 50, 1084-1092.
183. Takkenberg, B.; Zaaijer, H.; Weegink, C.; Terpstra, V.; Dijkgraaf, M.; Jansen, P.; Janssen, H.; Beld, M.; Reesinkg, H. Baseline HBsAg level predicts HBsAG loss in chronic hepatitis B patients treated with a combination of peginterferon alfa-2A and adefovir: An interim analysis. In Proceeding of the European Association Liver Disease 44th Annual Meeting, Copenhagen, Denmark, April 2009.
184. Moucari, R.; Boyer, N.; Ripault, M.P.; Castelnau, C.; Mackiewicz, V.; Dauvergne, A.; Valla, D.; Vidaud, M.; Chanoine, M.H.; Marcellin, P. Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients. J. Viral. Hepat. 2010, doi:10.1111/j.1365-2893.2010.01332.x.
185. Das, K.; Xiong, X.; Yang, H.; Westland, C.E.; Gibbs, C.S.; Sarafianos, S.G.; Arnold, E. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J. Virol. 2001, 75, 4771-4779.
186. Bartholomeusz, A.; Tehan, B.G.; Chalmers, D.K. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir. Ther. 2004, 9, 149-160.
187. Stuyver, L.J.; Locarnini, S.A.; Lok, A.; Richman, D.D.; Carman, W.F.; Dienstag, J.L.; Schinazi, R.F. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001, 33, 751-757.
188. Lai, C.L.; Dienstag, J.; Schiff, E.; Leung, N.W.; Atkins, M.; Hunt, C.; Brown, N.; Woessner, M.; Boehme, R.; Condreay, L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 2003, 36, 687-696.
189. Marcellin, P.; Lau, G.K.; Bonino, F.; Farci, P.; Hadziyannis, S.; Jin, R.; Lu, Z.M.; Piratvisuth, T.; Germanidis, G.; Yurdaydin, C.; et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2004, 351, 1206-1217.
190. Lok, A.S.; Lai, C.L.; Leung, N.; Yao, G.B.; Cui, Z.Y.; Schiff, E.R.; Dienstag, J.L.; Heathcote, E.J.; Little, N.R.; Griffiths, D.A.; et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125, 1714-1722.
191. Tipples, G.A.; Ma, M.M.; Fischer, K.P.; Bain, V.G.; Kneteman, N.M.; Tyrrell, D.L. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996, 24, 714-717.
192. Allen, M.I.; Deslauriers, M.; Andrews, C.W.; Tipples, G.A.; Walters, K.A.; Tyrrell, D.L.; Brown, N.; Condreay, L.D. Identification and characterization of mutations in hepatitis B Virus Res.istant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27, 1670-1677.
193. Ono, S.K.; Kato, N.; Shiratori, Y.; Kato, J.; Goto, T.; Schinazi, R.F.; Carrilho, F.J.; Omata, M. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest. 2001, 107, 449-455
194. Delaney, W.E.t.; Yang, H.; Westland, C.E.; Das, K.; Arnold, E.; Gibbs, C.S.; Miller, M.D.; Xiong, S. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J. Virol. 2003, 77, 11833-11841.
195. Warner, N.; Locarnini, S.; Kuiper, M.; Bartholomeusz, A.; Ayres, A.; Yuen, L.; Shaw, T. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob. Agents Chemother. 2007, 51, 2285-2292.
196. Liaw, Y.F.; Gane, E.; Leung, N.; Zeuzem, S.; Wang, Y.; Lai, C.L.; Heathcote, E.J.; Manns, M.; Bzowej, N.; Niu, J.; et al. 2-Year GLOBE trial results: Telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136, 486-495.
197. Tenney, D.J.; Levine, S.M.; Rose, R.E.; Walsh, A.W.; Weinheimer, S.P.; Discotto, L.; Plym, M.; Pokornowski, K.; Yu, C.F.; Angus, P.; et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob. Agents Chemother. 2004, 48, 3498-3507.
198. Tenney, D.J.; Rose, R.E.; Baldick, C.J.; Levine, S.M.; Pokornowski, K.A.; Walsh, A.W.; Fang, J.; Yu, C.F.; Zhang, S.; Mazzucco, C.E.; et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother. 2007, 51, 902-911.
199. Sherman, M.; Yurdaydin, C.; Simsek, H.; Silva, M.; Liaw, Y.F.; Rustgi, V.K.; Sette, H.; Tsai, N.; Tenney, D.J.; Vaughan, J.; et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008, 48, 99-108.
200. Tenney, D.J.; Rose, R.E.; Baldick, C.J.; Pokornowski, K.A.; Eggers, B.J.; Fang, J.; Wichroski, M.J.; Xu, D.; Yang, J.; Wilber, R.B.; et al. Long-term monitoring shows hepatitis B Virus Res.istance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009, 49, 1503-1514.
201. Choe, W.H.; Hong, S.P.; Kim, B.K.; Ko, S.Y.; Jung, Y.K.; Kim, J.H.; Yeon, J.E.; Byun, K.S.; Kim, K.H.; Ji, S.I.; et al. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antivir. Ther. 2009, 14, 985-993.
202. Chang, T.T.; Gish, R.G.; Hadziyannis, S.J.; Cianciara, J.; Rizzetto, M.; Schiff, E.R.; Pastore, G.; Bacon, B.R.; Poynard, T.; Joshi, S.; et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005, 129, 1198-1209.
203. Westland, C.E.; Yang, H.; Delaney, W.E.T.; Gibbs, C.S.; Miller, M.D.; Wulfsohn, M.; Fry, J.; Brosgart, C.L.; Xiong, S. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003, 38, 96-103.
204. Hadziyannis, S.J.; Tassopoulos, N.C.; Heathcote, E.J.; Chang, T.T.; Kitis, G.; Rizzetto, M.; Marcellin, P.; Lim, S.G.; Goodman, Z.; Ma, J.; et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2005, 352, 2673-2681.
205. Hadziyannis, S.J.; Tassopoulos, N.C.; Heathcote, E.J.; Chang, T.T.; Kitis, G.; Rizzetto, M.; Marcellin, P.; Lim, S.G.; Goodman, Z.; Ma, J.; et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131, 1743-1751
206. Angus, P.; Vaughan, R.; Xiong, S.; Yang, H.; Delaney, W.; Gibbs, C.; Brosgart, C.; Colledge, D.; Edwards, R.; Ayres, A.; et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125, 292-297.
207. Fung, S.K.; Chae, H.B.; Fontana, R.J.; Conjeevaram, H.; Marrero, J.; Oberhelman, K.; Hussain, M.; Lok, A.S. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol. 2006, 44, 283-290.
208. Borroto-Esoda, K.; Miller, M.D.; Arterburn, S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J. Hepatol. 2007, 47, 492-498.
209. Santantonio, T.; Fasano, M.; Durantel, S.; Barraud, L.; Heichen, M.; Guastadisegni, A.; Pastore, G.; Zoulim, F. Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. Antivir. Ther. 2009, 14, 557-565.
210. Yang, H.; Westland, C.; Xiong, S.; Delaney, W.E.T. In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Antivir. Res. 2004, 61, 27-36.
211. Peters, M.G.; Hann Hw, H.; Martin, P.; Heathcote, E.J.; Buggisch, P.; Rubin, R.; Bourliere, M.; Kowdley, K.; Trepo, C.; Gray Df, D.; et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004, 126, 91-101.
212. Westland, C.E.; Yang, H.; Delaney, W.E.T.; Wulfsohn, M.; Lama, N.; Gibbs, C.S.; Miller, M.D.; Fry, J.; Brosgart, C.L.; Schiff, E.R.; et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J. Viral. Hepat. 2005, 12, 67-73.
213. Yang, H.; Qi, X.; Sabogal, A.; Miller, M.; Xiong, S.; Delaney, W.E.T. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir. Ther. 2005, 10, 625-633.
214. Rapti, I.; Dimou, E.; Mitsoula, P.; Hadziyannis, S.J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007, 45, 307-313.
215. Lok, A.S.; Zoulim, F.; Locarnini, S.; Bartholomeusz, A.; Ghany, M.G.; Pawlotsky, J.M.; Liaw, Y.F.; Mizokami, M.; Kuiken, C. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 2007, 46, 254-265.
216. Keeffe, E.B.; Dieterich, D.T.; Pawlotsky, J.M.; Benhamou, Y. Chronic hepatitis B: Preventing, detecting, and managing viral resistance. Clin. Gastroenterol. Hepatol. 2008, 6, 268-274.
217. Lok, A.S.; McMahon, B.J. Chronic hepatitis B: Update 2009. Hepatology 2009, 50, 661-662.
218. Yeh, C.T.; Chien, R.N.; Chu, C.M.; Liaw, Y.F. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000, 31, 1318-1326.
219. Yatsuji, H.; Noguchi, C.; Hiraga, N.; Mori, N.; Tsuge, M.; Imamura, M.; Takahashi, S.; Iwao, E.; Fujimoto, Y.; Ochi, H.; et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob. Agents Chemother. 2006, 50, 3867-3874.
220. Gerolami, R.; Bourliere, M.; Colson, P.; Halfon, P.; Borentain, P.; Henry, M.; Botta, D.; Thibault, V.; Khiri, H.; Tamalet, C. Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: Report of two cases. Antivir. Ther. 2006, 11, 1103-1106.
221. Villet, S.; Pichoud, C.; Billioud, G.; Barraud, L.; Durantel, S.; Trepo, C.; Zoulim, F. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J. Hepatol. 2008, 48, 747-755.
222. Warner, N.; Locarnini, S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008, 48, 88-98.
223. Zoulim, F.; Locarnini, S. Hepatitis B Virus Res.istance to nucleos(t)ide analogues. Gastroenterology 2009, 137, 1593-1608.e1591-e1592.
224. Tan, J.; Degertekin, B.; Wong, S.N.; Husain, M.; Oberhelman, K.; Lok, A.S. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J. Hepatol. 2008, 48, 391-398.
225. van Bommel, F.; de Man, R.A.; Wedemeyer, H.; Deterding, K.; Petersen, J.; Buggisch, P.; Erhardt, A.; Huppe, D.; Stein, K.; Trojan, J.; et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010, 51, 73-80.
226. Shaw, T.; Bartholomeusz, A.; Locarnini, S. HBV drug resistance: Mechanisms, detection and interpretation. J. Hepatol. 2006, 44, 593-606.
227. Schildgen, O.; Olotu, C.; Funk, A.; Zollner, B.; Helm, M.; Rockstroh, J.K.; Sirma, H. Selection and counterselection of the adefovir resistance mutation rtI233V during antiviral therapy. J. Clin. Microbiol. 2009, doi:10.1128/JCM.01073-09.
228. Schildgen, O.; Sirma, H.; Funk, A.; Olotu, C.; Wend, U.C.; Hartmann, H.; Helm, M.; Rockstroh, J.K.; Willems, W.R.; Will, H.; et al. Variant of hepatitis B virus with primary resistance to adefovir. N. Engl. J. Med. 2006, 354, 1807-1812.
229. Curtis, M.; Zhu, Y.; Borroto-Esoda, K. Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. J. Infect. Dis. 2007, 196, 1483-1486.
230. Sheldon, J.; Camino, N.; Rodes, B.; Bartholomeusz, A.; Kuiper, M.; Tacke, F.; Nunez, M.; Mauss, S.; Lutz, T.; Klausen, G.; et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir. Ther. 2005, 10, 727-734.
231. Qi, X.; Xiong, S.; Yang, H.; Miller, M.; Delaney, W.E.T. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir. Ther. 2007, 12, 355-362.
232. Burton, J.R., Jr.; Everson, G.T. HCV NS5B polymerase inhibitors. Clin. Liver Dis. 2009, 13, 453-465.
233. Sarrazin, C.; Zeuzem, S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010, 138, 447-462.
234. Naggie, S.; Patel, K.; McHutchison, J. Hepatitis C virus directly acting antivirals: Current developments with NS3/4A HCV serine protease inhibitors. J. Antimicrob. Chemother. 2010, 65, 2063-2069.
235. Gao, M.; Nettles, R.E.; Belema, M.; Snyder, L.B.; Nguyen, V.N.; Fridell, R.A.; Serrano-Wu, M.H.; Langley, D.R.; Sun, J.H.; O'Boyle, D.R., 2nd; et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010, 465, 96-100.
236. Lindenbach, B.D.; Evans, M.J.; Syder, A.J.; Wolk, B.; Tellinghuisen, T.L.; Liu, C.C.; Maruyama, T.; Hynes, R.O.; Burton, D.R.; McKeating, J.A.; et al. Complete replication of hepatitis C virus in cell culture. Science 2005, 309, 623-626.
237. Zhong, J.; Gastaminza, P.; Cheng, G.; Kapadia, S.; Kato, T.; Burton, D.R.; Wieland, S.F.; Uprichard, S.L.; Wakita, T.; Chisari, F.V. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 9294-9299.
238. Yi, M.; Villanueva, R.A.; Thomas, D.L.; Wakita, T.; Lemon, S.M. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 2310-2315.
239. Kato, T.; Matsumura, T.; Heller, T.; Saito, S.; Sapp, R.K.; Murthy, K.; Wakita, T.; Liang, T.J. Production of infectious hepatitis C virus of various genotypes in cell cultures. J. Virol. 2007, 81, 4405-4411.
240. Pang, P.S.; Planet, P.J.; Glenn, J.S. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS One 2009, 4, e6579.
241. Asselah, T.; Estrabaud, E.; Bieche, I.; Lapalus, M.; De Muynck, S.; Vidaud, M.; Saadoun, D.; Soumelis, V.; Marcellin, P. Hepatitis C: Viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 2010, 30, 1259-1269.
242. Jaeckel, E.; Cornberg, M.; Wedemeyer, H.; Santantonio, T.; Mayer, J.; Zankel, M.; Pastore, G.; Dietrich, M.; Trautwein, C.; Manns, M.P. Treatment of acute hepatitis C with interferon alfa-2b. N. Engl. J. Med. 2001, 345, 1452-1457.
243. Gerlach, J.T.; Diepolder, H.M.; Zachoval, R.; Gruener, N.H.; Jung, M.C.; Ulsenheimer, A.; Schraut, W.W.; Schirren, C.A.; Waechtler, M.; Backmund, M.; et al. Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003, 125, 80-88.
244. Farci, P.; Strazzera, R.; Alter, H.J.; Farci, S.; Degioannis, D.; Coiana, A.; Peddis, G.; Usai, F.; Serra, G.; Chessa, L.; et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 3081-3086.
245. Morishima, C.; Polyak, S.J.; Ray, R.; Doherty, M.C.; Di Bisceglie, A.M.; Malet, P.F.; Bonkovsky, H.L.; Sullivan, D.G.; Gretch, D.R.; Rothman, A.L.; et al. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J. Infect. Dis. 2006, 193, 931-940.
246. Veillon, P.; Payan, C.; Le Guillou-Guillemette, H.; Gaudy, C.; Lunel, F. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy. World J. Gastroenterol. 2007, 13, 1195-1203.
247. Aurora, R.; Donlin, M.J.; Cannon, N.A.; Tavis, J.E. Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J. Clin. Invest. 2009, 119, 225-236.
248. Chary, A.; Winters, M.A.; Kottilil, S.; Murphy, A.A.; Polis, M.A.; Holodniy, M. Impact of Interferon-Ribavirin Treatment on Hepatitis C Virus (HCV) Protease Quasispecies Diversity in HIV- and HCV-Coinfected Patients. J. Infect. Dis. 2010, 202, 889-893.
249. Enomoto, N.; Sakuma, I.; Asahina, Y.; Kurosaki, M.; Murakami, T.; Yamamoto, C.; Ogura, Y.; Izumi, N.; Marumo, F.; Sato, C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 1996, 334, 77-81.
250. Witherell, G.W.; Beineke, P. Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. J. Med. Virol. 2001, 63, 8-16.
251. Guo, J.T.; Sohn, J.A.; Zhu, Q.; Seeger, C. Mechanism of the interferon alpha response against hepatitis C virus replicons. Virology 2004, 325, 71-81.
252. Brillet, R.; Penin, F.; Hezode, C.; Chouteau, P.; Dhumeaux, D.; Pawlotsky, J.M. The nonstructural 5A protein of hepatitis C virus genotype 1b does not contain an interferon sensitivity-determining region. J. Infect. Dis. 2007, 195, 432-441.
253. Cannon, N.A.; Donlin, M.J.; Fan, X.; Aurora, R.; Tavis, J.E. Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. PLoS One 2008, 3, e2123.
254. Cuevas, J.M.; Torres-Puente, M.; Jimenez-Hernandez, N.; Bracho, M.A.; Garcia-Robles, I.; Wrobel, B.; Carnicer, F.; del Olmo, J.; Ortega, E.; Moya, A.; et al. Genetic variability of hepatitis C virus before and after combined therapy of interferon plus ribavirin. PLoS One 2008, 3, e3058.
255. Lau, J.Y.; Tam, R.C.; Liang, T.J.; Hong, Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002, 35, 1002-1009.
256. Shields, W.W.; Pockros, P.J. Ribavirin analogs. Clin. Liver Dis. 2009, 13, 419-427.
257. Maag, D.; Castro, C.; Hong, Z.; Cameron, C.E. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 2001, 276, 46094-46098.
258. Crotty, S.; Maag, D.; Arnold, J.J.; Zhong, W.; Lau, J.Y.; Hong, Z.; Andino, R.; Cameron, C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 2000, 6, 1375-1379.
259. Chevaliez, S.; Brillet, R.; Lazaro, E.; Hezode, C.; Pawlotsky, J.M. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J. Virol. 2007, 81, 7732-7741.
260. Penin, F.; Dubuisson, J.; Rey, F.A.; Moradpour, D.; Pawlotsky, J.M. Structural biology of hepatitis C virus. Hepatology 2004, 39, 5-19.
261. Kwong, A.D.; Kim, J.L.; Rao, G.; Lipovsek, D.; Raybuck, S.A. Hepatitis C virus NS3/4A protease. Antivir. Res. 1999, 41, 67-84.
262. Landro, J.A.; Raybuck, S.A.; Luong, Y.P.; OMalley, E.T.; Harbeson, S.L.; Morgenstern, K.A.; Rao, G.; Livingston, D.J. Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: Elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping. Biochemistry 1997, 36, 9340-9348.
263. Kieffer, T.L.; Kwong, A.D.; Picchio, G.R. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J. Antimicrob. Chemother. 2010, 65, 202-212.
264. Hezode, C.; Forestier, N.; Dusheiko, G.; Ferenci, P.; Pol, S.; Goeser, T.; Bronowicki, J.P.; Bourliere, M.; Gharakhanian, S.; Bengtsson, L.; et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 2009, 360, 1839-1850.
265. McHutchison, J.G.; Everson, G.T.; Gordon, S.C.; Jacobson, I.M.; Sulkowski, M.; Kauffman, R.; McNair, L.; Alam, J.; Muir, A.J. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 2009, 360, 1827-1838.
266. McHutchison, J.G.; Manns, M.P.; Muir, A.J.; Terrault, N.A.; Jacobson, I.M.; Afdhal, N.H.; Heathcote, E.J.; Zeuzem, S.; Reesink, H.W.; Garg, J.; et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 2010, 362, 1292-1303.
267. Berman, K.; Kwo, P.Y. Boceprevir, an NS3 protease inhibitor of HCV. Clin. Liver Dis. 2009, 13, 429-439.
268. Sarrazin, C.; Kieffer, T.L.; Bartels, D.; Hanzelka, B.; Muh, U.; Welker, M.; Wincheringer, D.; Zhou, Y.; Chu, H.M.; Lin, C.; et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132, 1767-1777.
269. Kieffer, T.L.; Sarrazin, C.; Miller, J.S.; Welker, M.W.; Forestier, N.; Reesink, H.W.; Kwong, A.D.; Zeuzem, S. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007, 46, 631-639.
270. Susser, S.; Welsch, C.; Wang, Y.; Zettler, M.; Domingues, F.S.; Karey, U.; Hughes, E.; Ralston, R.; Tong, X.; Herrmann, E.; et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009, 50, 1709-1718.
271. Reesink, H.W.; Fanning, G.C.; Farha, K.A.; Weegink, C.; Van Vliet, A.; Van 't Klooster, G.; Lenz, O.; Aharchi, F.; Marien, K.; Van Remoortere, P.; et al. Rapid HCV-RNA decline with once daily TMC435: A phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010, 138, 913-921.
272. Liverton, N.J.; Carroll, S.S.; Dimuzio, J.; Fandozzi, C.; Graham, D.J.; Hazuda, D.; Holloway, M.K.; Ludmerer, S.W.; McCauley, J.A.; McIntyre, C.J.; et al. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob. Agents Chemother. 2010, 54, 305-311.
273. Rajagopalan, R.; Misialek, S.; Stevens, S.K.; Myszka, D.G.; Brandhuber, B.J.; Ballard, J.A.; Andrews, S.W.; Seiwert, S.D.; Kossen, K. Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior. Biochemistry 2009, 48, 2559-2568.
274. Bartels, D.J.; Zhou, Y.; Zhang, E.Z.; Marcial, M.; Byrn, R.A.; Pfeiffer, T.; Tigges, A.M.; Adiwijaya, B.S.; Lin, C.; Kwong, A.D.; et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 2008, 198, 800-807.
275. Kuntzen, T.; Timm, J.; Berical, A.; Lennon, N.; Berlin, A.M.; Young, S.K.; Lee, B.; Heckerman, D.; Carlson, J.; Reyor, L.L.; et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008, 48, 1769-1778.
276. Thibeault, D.; Bousquet, C.; Gingras, R.; Lagace, L.; Maurice, R.; White, P.W.; Lamarre, D. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J. Virol. 2004, 78, 7352-7359.
277. Lopez-Labrador, F.X.; Moya, A.; Gonzalez-Candelas, F. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir. Ther. 2008, 13, 481-494.
278. Beyer, B.M.; Zhang, R.; Hong, Z.; Madison, V.; Malcolm, B.A. Effect of naturally occurring active site mutations on hepatitis C virus NS3 protease specificity. Proteins 2001, 43, 82-88.
279. Di Marco, S.; Rizzi, M.; Volpari, C.; Walsh, M.A.; Narjes, F.; Colarusso, S.; De Francesco, R.; Matassa, V.G.; Sollazzo, M. Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes. J. Biol. Chem. 2000, 275, 7152-7157.
280. Courcambeck, J.; Bouzidi, M.; Perbost, R.; Jouirou, B.; Amrani, N.; Cacoub, P.; Pepe, G.; Sabatier, J.M.; Halfon, P. Resistance of hepatitis C virus to NS3-4A protease inhibitors: Mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations. Antivir. Ther. 2006, 11, 847-855.
281. Prongay, A.J.; Guo, Z.; Yao, N.; Pichardo, J.; Fischmann, T.; Strickland, C.; Myers, J., Jr.; Weber, P.C.; Beyer, B.M.; Ingram, R.; et al. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl] - 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization. J. Med. Chem. 2007, 50, 2310-2318.
282. Frecer, V.; Kabelac, M.; De Nardi, P.; Pricl, S.; Miertus, S. Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus. J. Mol. Graph. Model. 2004, 22, 209-220.
283. McCown, M.F.; Rajyaguru, S.; Le Pogam, S.; Ali, S.; Jiang, W.R.; Kang, H.; Symons, J.; Cammack, N.; Najera, I. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 2008, 52, 1604-1612.
284. Ali, S.; Leveque, V.; Le Pogam, S.; Ma, H.; Philipp, F.; Inocencio, N.; Smith, M.; Alker, A.; Kang, H.; Najera, I.; et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob. Agents Chemother. 2008, 52, 4356-4369.
285. He, Y.; King, M.S.; Kempf, D.J.; Lu, L.; Lim, H.B.; Krishnan, P.; Kati, W.; Middleton, T.; Molla, A. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob. Agents Chemother. 2008, 52, 1101-1110.
286. Carroll, S.S.; Ludmerer, S.; Handt, L.; Koeplinger, K.; Zhang, N.R.; Graham, D.; Davies, M.E.; MacCoss, M.; Hazuda, D.; Olsen, D.B. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob. Agents Chemother. 2009, 53, 926-934.
287. Migliaccio, G.; Tomassini, J.E.; Carroll, S.S.; Tomei, L.; Altamura, S.; Bhat, B.; Bartholomew, L.; Bosserman, M.R.; Ceccacci, A.; Colwell, L.F.; et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 2003, 278, 49164-49170.
288. Le Pogam, S.; Jiang, W.R.; Leveque, V.; Rajyaguru, S.; Ma, H.; Kang, H.; Jiang, S.; Singer, M.; Ali, S.; Klumpp, K.; et al. In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 2006, 351, 349-359.
289. Pockros, P.J.; Nelson, D.; Godofsky, E.; Rodriguez-Torres, M.; Everson, G.T.; Fried, M.W.; Ghalib, R.; Harrison, S.; Nyberg, L.; Shiffman, M.L.; et al. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008, 48, 385-397.
290. Gane, E.J.; Roberts, S.K.; Stedman, C.A.; Angus, P.W.; Ritchie, B.; Elston, R.; Ipe, D.; Morcos, P.N.; Baher, L.; Najera, I.; et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010, 376, 1467-1475.
291. Wang, M.; Ng, K.K.; Cherney, M.M.; Chan, L.; Yannopoulos, C.G.; Bedard, J.; Morin, N.; Nguyen-Ba, N.; Alaoui-Ismaili, M.H.; Bethell, R.C.; et al. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J. Biol. Chem. 2003, 278, 9489-9495.
292. Kukolj, G.; McGibbon, G.A.; McKercher, G.; Marquis, M.; Lefebvre, S.; Thauvette, L.; Gauthier, J.; Goulet, S.; Poupart, M.A.; Beaulieu, P.L. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J. Biol. Chem. 2005, 280, 39260-39267.
293. Hang, J.Q.; Yang, Y.; Harris, S.F.; Leveque, V.; Whittington, H.J.; Rajyaguru, S.; Ao-Ieong, G.; McCown, M.F.; Wong, A.; Giannetti, A.M.; et al. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus. J. Biol. Chem. 2009, 284, 15517-15529.
294. Le Pogam, S.; Kang, H.; Harris, S.F.; Leveque, V.; Giannetti, A.M.; Ali, S.; Jiang, W.R.; Rajyaguru, S.; Tavares, G.; Oshiro, C.; et al. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J. Virol. 2006, 80, 6146-6154.
295. Pauwels, F.; Mostmans, W.; Quirynen, L.M.; van der Helm, L.; Boutton, C.W.; Rueff, A.S.; Cleiren, E.; Raboisson, P.; Surleraux, D.; Nyanguile, O.; et al. Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors. J. Virol. 2007, 81, 6909-6919.
296. Howe, A.Y.; Cheng, H.; Johann, S.; Mullen, S.; Chunduru, S.K.; Young, D.C.; Bard, J.; Chopra, R.; Krishnamurthy, G.; Mansour, T.; et al. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob. Agents Chemother. 2008, 52, 3327-3338.
297. Le Pogam, S.; Seshaadri, A.; Kosaka, A.; Chiu, S.; Kang, H.; Hu, S.; Rajyaguru, S.; Symons, J.; Cammack, N.; Najera, I. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J. Antimicrob. Chemother. 2008, 61, 1205-1216.
298. Gaudieri, S.; Rauch, A.; Pfafferott, K.; Barnes, E.; Cheng, W.; McCaughan, G.; Shackel, N.; Jeffrey, G.P.; Mollison, L.; Baker, R.; et al. Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy. Hepatology 2009, 49, 1069-1082.
299. Tellinghuisen, T.L.; Foss, K.L.; Treadaway, J.C.; Rice, C.M. Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J. Virol. 2008, 82, 1073-1083.
300. Tellinghuisen, T.L.; Marcotrigiano, J.; Rice, C.M. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 2005, 435, 374-379.
301. Lemm, J.A.; OBoyle, D., 2nd; Liu, M.; Nower, P.T.; Colonno, R.; Deshpande, M.S.; Snyder, L.B.; Martin, S.W.; St Laurent, D.R.; Serrano-Wu, M.H.; et al. Identification of hepatitis C virus NS5A inhibitors. J. Virol. 2010, 84, 482-491.
302. Fridell, R.A.; Qiu, D.; Wang, C.; Valera, L.; Gao, M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 2010, 54, 3641-3650.
303. Yang, F.; Robotham, J.M.; Grise, H.; Frausto, S.; Madan, V.; Zayas, M.; Bartenschlager, R.; Robinson, M.; Greenstein, A.E.; Nag, A.; et al. A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach. PLoS Pathog. 2010, 6, e1001118.
304. Flisiak, R.; Feinman, S.V.; Jablkowski, M.; Horban, A.; Kryczka, W.; Pawlowska, M.; Heathcote, J.E.; Mazzella, G.; Vandelli, C.; Nicolas-Metral, V.; et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009, 49, 1460-1468.
305. Chatterji, U.; Lim, P.; Bobardt, M.D.; Wieland, S.; Cordek, D.G.; Vuagniaux, G.; Chisari, F.; Cameron, C.E.; Targett-Adams, P.; Parkinson, T.; et al. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J. Hepatol. 2010, 53, 50-56.
306. Di Marco, V.; Di Stefano, R.; Ferraro, D.; Almasio, P.L.; Bonura, C.; Giglio, M.; Parisi, P.; Cappello, M.; Alaimo, G.; Craxi, A. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir. Ther. 2005, 10, 431-439.
307. Erhardt, A.; Deterding, K.; Benhamou, Y.; Reiser, M.; Forns, X.; Pol, S.; Calleja, J.L.; Ross, S.; Spangenberg, H.C.; Garcia-Samaniego, J.; et al. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir. Ther. 2009, 14, 23-32.
308. Hirashima, S.; Suzuki, T.; Ishida, T.; Noji, S.; Yata, S.; Ando, I.; Komatsu, M.; Ikeda, S.; Hashimoto, H. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: Structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J. Med. Chem. 2006, 49, 4721-4736.
309. Cooper, C.; Lawitz, E.J.; Ghali, P.; Rodriguez-Torres, M.; Anderson, F.H.; Lee, S.S.; Bedard, J.; Chauret, N.; Thibert, R.; Boivin, I.; et al. Evaluation of VCH-759 monotherapy in hepatitis C infection. J. Hepatol. 2009, 51, 39-46.
310. Tomei, L.; Altamura, S.; Bartholomew, L.; Bisbocci, M.; Bailey, C.; Bosserman, M.; Cellucci, A.; Forte, E.; Incitti, I.; Orsatti, L.; et al. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J. Virol. 2004, 78, 938-946.
311. McCown, M.F.; Rajyaguru, S.; Kular, S.; Cammack, N.; Najera, I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob. Agents Chemother. 2009, 53, 2129-2132